REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021 • Clinical Capabilities
All patients have been registered at ten sites in Japan for the Phase II clinical trial of Stemchymal®, a human adipose-derived stem cell product exclusively licensed in Japan by Steminent Biotherapeutics Inc. (hereinafter referred to as Steminent), where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with spinocerebellar ataxia (SCA).Read more →
16 February 2021 • Stem Cells
[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the new distributor of its Maestro systems and consumables in India.Read more →
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020 • Clinical Capabilities
17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from January 2021 in Japan. REPROCELL has also launched a new B2C website to promote the Personal iPS service, which is currently only available in Japan.
10 December 2020 •
Beltsville, USA: REPROCELL, an industry leader in the use of human biospecimens for medical research, has partnered with Scientist.com, the healthcare industry’s leading marketplace for life science research, to bring its services to the global biotechnology community. REPROCELL joins a select group of highly-rated marketplace VIP suppliers that commit to outstanding customer service and offer a discount to biotech customers.Read more →
17 August 2020 • Clinical Capabilities
eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020 • Drug Discovery
March 19, 2020Read more →
15 July 2020 • Stem Cells
Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells.
StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This model was developed using advanced technologies established by Professor Shoen Kume (The Tokyo Institute of Technology) and REPROCELL, Inc. StemRNA™ Entero cells closely mimic the gene expression of intestinal epithelial cells; for example, they express high levels of the CYP3A4 gene – a key enzyme for metabolism – compared to Caco2 cells, an intestinal model system widely used to measure the absorption and metabolism of novel therapeutics. StemRNA™ Entero cells are designed for use as a more clinically relevant alternative to Caco2 cells in drug development.Read more →
30 March 2020 •
The lab-scale system will allow researchers to study and culture stem cells in suspension
Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.
“We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.Read more →
28 February 2020 • Clinical Capabilities